BW

11
Dic
By MetroLatinoUSA
BW

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting

– Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell therapy – – WU-NK-101 exhibited enhanced anti-tumor activity, robust bone marrow trafficking, and metabolic flexibility – – Phase 1 clinical study of WU-NK-101 for off-the-shelf treatment of patients with relapsed…
Leer más...
11
Dic
By MetroLatinoUSA
BW

Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth

– The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe hemophilia A without inhibitors – – 77.8% of participants had no bleeding episodes that required treatment – – In addition, real-world…
Leer más...
10
Dic
By MetroLatinoUSA
BW

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition

23 of 26 (88%) patients remained free of clinically significant infections caused by any of six common viruses that posoleucel targets through the Week 14 primary endpoint 3 of 26 (12%) patients had clinically significant infections despite 22 of 26 (85%) patients reactivating one or more of six potentially devastating…
Leer más...
10
Dic
By MetroLatinoUSA
BW

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progyny, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--$PGNY #PGNY--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Progyny, Inc. (“Progyny” or “the Company”) (NASDAQ: PGNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements…
Leer más...
10
Dic
By MetroLatinoUSA
BW

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims on Behalf of Investors in FTX Tokens

LOS ANGELES--(BUSINESS WIRE)--$FTT #FTT--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in FTX Tokens (FTT) against FTX Trading Ltd. (“FTX”) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022

- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) - Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia…
Leer más...
10
Dic
By MetroLatinoUSA
BW

Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th ASH Annual Meeting

– Updated data from Phase 1b/2 trials include 151 patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes and other hematological malignancies – – Relapse-free survival was 87% at one year in a group of 71 patients who received the preferred conditioning regimen being used in the Precision-T Phase…
Leer más...
10
Dic
By MetroLatinoUSA
BW

MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting

Oral presentation at 64th American Society of Hematology Annual Meeting includes promising results from 81 patients with steroid-resistant, gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) treated with MaaT013 as part of compassionate use program (Early Access Program or EAP) in France. Results showed a GI-Overall Response Rate (ORR) of 56% including 30…
Leer más...
¡Síguenos en Facebook!
¡Síguenos en Twitter!